Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
3.22 USD 0.00(0%)
Last update at 2024-11-01T13:30:00Z
Market Cap
11.88M

Momentum Score

…

Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.22
Low
3.22
High
52 Week Price Range
5.01
Low
10.75
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
3.22
Dividend Yield
-
Revenue TTM
12.06M
Revenue Per Share
9.47
Gross Profit TTM
4.52M
Debt / Equity
0.00
ROE
-86.11%
Net Debt
-6.36M
ROCE
4.08%
Diluted EPS TTM
-4.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -14.92M -24.75M -8.57M -10.88M -7.77M
Minority interest - - - - 0.00M
Net income -30.28M -24.75M -8.58M -11.14M -7.77M
Selling general administrative 9.58M 11.20M 6.83M 7.43M 4.93M
Selling and marketing expenses 2.07M 2.32M 1.45M 1.87M 1.52M
Gross profit 4.52M 3.11M -0.06M 0.56M 0.54M
Reconciled depreciation 1.25M 0.91M 0.22M 0.63M 0.30M
Ebit 0.43M -10.48M -8.55M -8.93M -6.14M
Ebitda 1.68M -9.57M -8.28M -8.72M -5.85M
Depreciation and amortization 1.25M 0.91M 0.27M 0.21M 0.30M
Non operating income net other - - -0.01M - -
Operating income 0.43M -10.48M -8.55M -8.93M -6.14M
Other operating expenses 18.37M 17.72M 10.39M 9.84M 7.09M
Interest expense 15.35M 0.00M 0.01M 0.26M 0.00M
Interest income 0.15M 0.00M - 0.03M 1.62M
Net interest income 0.15M 0.00M -0.01M -0.67M -0.00M
Extraordinary items - - - - 0.00M
Non recurring - - 0.05M - 0.00M
Other items - - - - 0.00M
Income tax expense 15.35M 14.26M 0.01M 0.26M -1.62M
Total revenue 11.05M 7.23M 1.89M 0.90M 0.94M
Total operating expenses 11.84M 13.59M 8.45M 9.50M 6.69M
Cost of revenue 6.53M 4.12M 1.95M 0.34M 0.40M
Total other income expense net -15.35M -14.26M -0.02M -1.94M -1.62M
Discontinued operations - - - - 0.00M
Net income from continuing ops -14.92M -24.75M -8.57M -10.88M -7.77M
Net income applicable to common shares -15.86M -24.75M -8.57M -10.88M -7.77M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 11.92M 21.69M 23.46M 9.86M 12.88M
Intangible assets - - 11.26M 0.05M 0.05M
Other current assets 0.57M 0.69M 1.20M 0.18M 0.36M
Total liab 3.77M 8.52M 1.16M 1.35M 0.84M
Total stockholder equity 8.15M 13.17M 22.30M 8.52M 12.03M
Other current liab 0.70M 2.49M 0.90M 0.03M 0.01M
Common stock 0.00M 0.00M 0.02M 0.02M 0.07M
Capital stock 0.00M 5.25M 0.02M 0.02M 0.07M
Retained earnings -93.57M -93.72M -78.80M -54.08M -45.51M
Other liab - 4.51M - - -
Good will - - - - 0.00M
Other assets - - - 0.01M 0.01M
Cash 6.36M 10.66M 4.09M 8.52M 11.12M
Total current liabilities 1.32M 4.01M 1.16M 1.07M 0.41M
Current deferred revenue - - - 0.28M 0.12M
Net debt -6.36M -10.65M -4.07M -8.08M -10.53M
Short term debt - 0.00M 0.02M 0.16M 0.15M
Short long term debt total - 0.00M 0.03M 0.43M 0.59M
Other stockholder equity 101.71M 101.64M 101.08M 62.58M 57.47M
Property plant equipment - 0.05M 0.14M 0.70M 0.95M
Total current assets 11.88M 21.64M 12.07M 9.09M 11.87M
Net tangible assets - 7.92M 11.04M 8.47M 11.98M
Short term investments - 0.00M 5.00M - -
Net receivables 2.27M 1.92M 1.41M 0.01M 0.08M
Inventory 2.68M 3.12M 0.37M 0.38M 0.31M
Accounts payable 0.61M 1.52M 0.24M 0.61M 0.13M
Accumulated other comprehensive income -11.92M - - - -0.38M
Common stock total equity - - - 0.02M 0.07M
Retained earnings total equity - - - -54.08M -
Non currrent assets other - - - 0.01M 0.01M
Non current assets total 0.03M 0.05M 11.39M 0.77M 1.01M
Capital lease obligations 0.00M 0.00M 0.03M 0.43M 0.59M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 4.99M -31.01M -0.03M -0.17M -0.31M
Change to liabilities 1.28M -0.68M 0.48M -0.01M 0.10M
Total cashflows from investing activities 4.99M -31.01M -0.03M -0.17M -0.31M
Net borrowings - - - 0.25M -0.18M
Total cash from financing activities 14.27M 37.23M 5.45M 16.65M 0.42M
Change to operating activities -0.27M -0.59M -0.12M -0.42M 0.14M
Net income -14.92M -24.75M -8.57M -10.88M -7.77M
Change in cash 11.81M -4.42M -2.60M 10.44M -4.06M
Begin period cash flow 4.09M 8.52M 11.12M 0.67M 4.74M
End period cash flow 15.91M 4.09M 8.52M 11.12M 0.67M
Total cash from operating activities -7.45M -10.64M -8.01M -6.03M -4.17M
Issuance of capital stock 13.14M 33.66M 0.00M 16.22M 0.85M
Depreciation 1.25M 0.91M 0.22M 0.63M 0.30M
Other cashflows from investing activities - - 0.01M - 0.00M
Dividends paid - - - - 0.00M
Change to inventory -2.81M 0.45M -0.73M 0.05M -0.20M
Change to account receivables -0.09M 0.38M 0.07M -0.05M 0.04M
Sale purchase of stock -0.01M -70.95M 5.45M 16.40M 0.87M
Other cashflows from financing activities 5.44M 3.57M 5.45M 0.52M -0.40M
Change to netincome 8.12M 13.63M 0.64M 4.41M 3.22M
Capital expenditures 0.01M 0.07M 0.04M 0.17M 0.31M
Change receivables - - 0.08M - -
Cash flows other operating - - -1.06M - -
Cash and cash equivalents changes - - -2.60M - -
Change in working capital -1.89M -0.44M -0.30M -0.43M 0.08M
Stock based compensation - 0.00M -0.40M 2.72M 1.60M
Other non cash items 8.12M 13.63M -0.94M 0.67M 1.62M
Free cash flow -7.45M -10.72M -8.05M -6.20M -4.48M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GHSI
Guardion Health Sciences Inc
-
-%
3.22 - - 0.83 1.25 0.39 -1.21
MKKGY
Merck KGaA ADR
-0.22
0.66%
33.17 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
-2.76
1.62%
167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR
-0.17
0.80%
21.02 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.
-
-%
41.85 - 10.66 0.01 1.16 2.94 23.11

Profile*

Guardion Health Sciences Inc

Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.

2925 Richmond Avenue, Houston, TX, United States, 77098

800 873 5141

9

Name Title Year Born
Mr. Robert Neal Weingarten Independent Chairman & Sec. 1952
Mr. Bret D. Scholtes Pres, CEO & Director 1970
Mr. Craig J. Sheehan Chief Commercial Officer 1971
Mr. Jeffrey Benjamin Chief Accounting Officer 1965
Mr. Robert Neal Weingarten Independent Chairman & Secretary 1952
Ms. Janet Hall President & CEO 1959
Ms. Katie Cox Chief Accounting Officer 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…